Navigation Links
Calithera Biosciences Secures $35 Million in Series D Financing
Date:10/29/2013

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the successful completion of a $35 million Series D financing led by Adage Capital Partners, LP.  Joining Adage as new investors in this financing are the Longwood Fund and two other institutional investor groups.  Existing investors Morgenthaler Ventures, Advanced Technology Ventures and Delphi Ventures, who have funded the company through earlier rounds of financing, also participated in the transaction.  In conjunction with this financing, Christoph Westphal, MD, PhD, Partner and Co-Founder of the Longwood Fund, will join Calithera's Board of Directors as an observer.

Calithera will use the proceeds from the financing to accelerate the development of the company's lead clinical-stage candidate CB-839 through Phase 1 clinical trials in patients with advanced solid and hematological tumors.  CB-839 is a potent and selective orally bioavailable glutaminase inhibitor that blocks the growth and survival of many different types of cancer cells by interfering with their metabolism of glutamine.  Calithera will also continue to develop its pipeline of novel therapeutics, including an inhibitor of MCL-1, an anti-apoptotic BCL-2 homolog over-expressed in many cancers.

"With this strong support from new and current investors, we will advance CB-839 through an early set of clinical trials aimed at identifying specific populations of cancer patients with glutamine-dependent tumors that would benefit from treatment with CB-839," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera Biosciences.  "CB-839 has demonstrated promising anti-tumor activity in a broad range of tumor types that depend on glutaminase for cell growth and survival.  We look forward to initiating clinical studies for CB-839."

"The Calithera team possesses an impressive track record in discovering and developing successful oncology drugs," said Christoph Westphal.  "Calithera's drug, CB-839, is an important new therapeutic candidate that has the pharmacological characteristics necessary to compete as a successful commercial oncology product.  We look forward to CB-839 and additional innovative pipeline candidates entering clinical trials and making significant contributions to the advancement of cancer therapy."

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing.  Calithera Biosciences is a privately held company located in South San Francisco, CA.  For more information, please visit www.calithera.com.


'/>"/>
SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video editors ... in a scene," said Christina Austin - CEO of Pixel Film Studios. , Video ... create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual ... alumni, family, friends, and community. “Coming Home 2017” will be held on ...
(Date:1/21/2017)... ... 2017 , ... In the United States, 20 million women and 10 million ... often feel shame for having struggled with an eating disorder as well as common ... Strong in Life After an Eating Disorder” -- to be featured at this year’s ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out of ... show to continue the marketing and distribution of its product, The Right C. , ... percent better absorption than traditional vitamin C supplements. At the trade show, Doctor C ...
Breaking Medicine News(10 mins):